Parkinson’s Disease Quality of Life questionnaire

1. Abstract

The Parkinson’s Disease Quality of Life questionnaire (PDQL) is a disease-specific health-related quality of life (HRQoL) patient-reported outcome measure developed in 1996 by Angela G. E. M. de Boer and colleagues. Created to capture the nuanced, multifaceted impact of Parkinson’s disease on daily physical, psychological, and social functioning, the PDQL addresses the critical need for an instrument sensitive to both motor and non-motor manifestations of neurodegenerative progression over an evaluative recall window of the preceding three months. The instrument comprises 37 items distributed across four empirically validated subscales: Parkinson Symptoms, Systemic Symptoms, Emotional Functioning, and Social Functioning. Responses are recorded on a five-point Likert scale ranging from 1 to 5, where item responses are summed such that higher numerical totals reflect superior quality of life and lower perceived symptom burden.

Psychometric evaluations across international cohorts demonstrate robust psychometric properties. Internal consistency reliability is high, with subscale Cronbach’s alpha coefficients consistently ranging between 0.73 and 0.89, and the overall scale achieving alpha values exceeding 0.93. Test-retest reliability across multi-week intervals demonstrates strong stability (intraclass correlation coefficients typically between 0.78 and 0.90). Construct validity is evidenced by significant correlations with the Unified Parkinson’s Disease Rating Scale (UPDRS), the Hoehn and Yahr staging scale, and generic health status indices such as the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). Factor analytic investigations confirm a stable four-factor dimensionality reflecting the multidimensional nature of neurodegenerative health experiences. The PDQL serves as a valuable clinical assessment tool, therapeutic monitoring device, and clinical trial endpoint in pharmacological and multidisciplinary neurorehabilitation research.

2. Keywords

Parkinson’s disease, PDQL, Health-Related Quality of Life, psychometrics, patient-reported outcome measures, neurodegenerative disorders, Unified Parkinson’s Disease Rating Scale, emotional functioning, systemic symptoms, social functioning, chronic illness assessment, motor symptoms

3. Authors

The Parkinson’s Disease Quality of Life questionnaire was developed and psychometrically validated by an interdisciplinary research team of medical psychologists, clinical epidemiologists, and neurologists in the Netherlands:

• Angela G. E. M. de Boer, PhD: Department of Medical Psychology and Coronel Institute of Occupational Health, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
• Wim Wijker, PhD: Department of Medical Psychology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
• J. D. Speelman, MD, PhD: Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
• J. C. J. M. de Haes, PhD: Department of Medical Psychology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Correspondence regarding the original developmental validation was directed through the Department of Medical Psychology, Academic Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.

4. Purpose

Parkinson’s disease is a chronic, progressive movement disorder characterized by cardinal motor signs including tremor, bradykinesia, rigidity, and postural instability, accompanied by a myriad of non-motor symptoms such as autonomic dysfunction, sleep disturbances, fatigue, cognitive slowing, depression, and social stigmatization. For decades, clinical efficacy in neurology was gauged almost exclusively through objective physical indices, biomarker tracking, and physician-rated impairment metrics, notably the Hoehn and Yahr staging and motor examinations of the UPDRS. However, these objective ratings often correlate weakly with a patient’s subjective sense of well-being, autonomy, and existential satisfaction. The primary purpose of the PDQL is to provide a standardized, psychometrically rigorous, patient-centered instrument capable of quantifying the holistic lived experience of individuals diagnosed with Parkinson’s disease.

Clinically, the instrument was conceived to fulfill three primary objectives:

• Diagnostic Complementation: Enabling healthcare providers to identify hidden burdens—such as silent psychological distress, sexual dysfunction, autonomic dysregulation, and social embarrassment—that are not captured in routine neurological physical examinations.
• Treatment Evaluation and Monitoring: Tracking subtle changes in patient functioning over time in response to pharmacotherapy (e.g., levodopa dosage optimization, dopamine agonist titration), surgical interventions (e.g., deep brain stimulation), and allied health therapies (e.g., physiotherapy, occupational therapy, speech pathology).
• Clinical Trial Endpoint Measurement: Serving as an evaluative endpoint in clinical trials that satisfies the regulatory guidelines set forth by agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding Patient-Reported Outcome (PRO) integration.

A distinctive feature of the PDQL’s design is its specific evaluative recall period of the preceding three months. While short recall windows (such as 24 hours or one week) are vulnerable to acute day-to-day motor fluctuations, dyskinesias, and “on-off” phenomena, the three-month window captures baseline clinical progression and sustained lifestyle disruption. Furthermore, the questionnaire was intentionally structured for self-administration by the patient or assisted administration via a trained interviewer, ensuring inclusivity for patients experiencing severe motor impairments, micrographic writing difficulties, or mild cognitive decline.

5. Psychological Construct

The construct operationalized by the PDQL is Disease-Specific Health-Related Quality of Life. Rather than treating quality of life as a monolithic or generic phenomenon, the PDQL conceptualizes it as a multidimensional mosaic governed by the interaction between chronic neurological deficits and the patient’s psychological adaptability, systemic somatic status, and interpersonal context. The 37 items coalesce into four distinct yet interconnected subscale dimensions:

1. Parkinson Symptoms (Parkinsonian Symptoms)

This subscale comprises items reflecting the direct functional consequences of primary striatal dopamine depletion. It encompasses motor manifestations and physical performance constraints, including difficulty walking, gait freezing, impaired balance, fine-motor coordination issues (e.g., buttoning clothes, handling cutlery, handwriting), muscular stiffness, and involuntary resting tremors. Rather than quantifying tremor frequency in Hertz or muscle tone via rigidity scales, the construct measures the degree to which these motor intrusions interfere with fundamental activities of daily living and subjective physical competence.

2. Systemic Symptoms

Recognizing that Parkinson’s disease is a multisystem neurodegenerative condition involving extranigral pathology and autonomic pathways, this dimension focuses on non-motor, general somatic complaints. Items probe manifestations such as chronic musculoskeletal pain, physical exhaustion, constipation, sleep fragmentation, orthostatic dizziness, and urinary disturbances. This subscale reflects how systemic physiological disruptions diminish an individual’s vitality and somatic comfort, providing a crucial counterbalance to purely motor-oriented rating scales.

3. Emotional Functioning

The emotional functioning subscale captures affective and psychological well-being. Chronic neurodegeneration frequently provokes reactive psychological distress while simultaneously inducing neurobiological alterations in serotonergic, noradrenergic, and mesolimbic dopaminergic pathways that predispose patients to clinical depression, generalized anxiety, panic, and anhedonia. Items in this dimension measure emotional vulnerability, feelings of despair, anxiety regarding disease progression, frustration over physical dependency, fluctuating mood states, and diminished self-worth. It captures the psychological adaptation and coping mechanisms deployed by the patient in facing an incurable illness.

4. Social Functioning

The social functioning dimension evaluates the sociological and interpersonal consequences of the condition. Parkinsonian symptoms often induce self-consciousness, shame, and social withdrawal due to visible signs like kinetic tremors, facial masking (hypomimia), dysarthric speech, and sialorrhea. This dimension assesses feelings of social isolation, avoidance of public dining or community gatherings, disruption of hobbies and recreation, perceived strain on family relationships, and loss of reciprocal social engagement. It operationalizes social health as both the maintenance of external interpersonal ties and the subjective absence of stigmatization.

6. Theoretical Framework

The structural and conceptual foundation of the PDQL is rooted in modern biopsychosocial paradigms of health and functioning, primarily informed by the Biopsychosocial Model articulated by George Engel (1977) and the disablement models formulated by the World Health Organization (WHO), which culminated in the International Classification of Functioning, Disability and Health (ICF).

Biopsychosocial Integration in Chronic Illness

Under Engel’s framework, disease cannot be understood purely as a mechanical, biological malfunction; biological pathology interacts with psychological vulnerabilities and interpersonal social networks. The PDQL was deliberately formulated to overcome the reductionism of the traditional biomedical model in clinical neurology. By measuring biological symptoms (Parkinson and Systemic Symptoms) alongside psychological states (Emotional Functioning) and environmental/relational contexts (Social Functioning), the scale translates the biopsychosocial architecture into quantitative psychometric indices.

The Disablement Process and Quality of Life Modeling

The scale aligns conceptually with the Disablement Process framework developed by Verbrugge and Jette (1994), which delineates the trajectory from pathology (degeneration of dopaminergic neurons in the substantia nigra pars compacta) to impairment (rigidity, bradykinesia, autonomic dysfunction), functional limitation (reduced walking speed, impaired manual dexterity), and finally disability (inability to perform professional roles, engage in community life, or maintain self-care). The PDQL acknowledges that quality of life is not identical to physical impairment; rather, HRQoL represents the subjective, evaluative gap between an individual’s actual functional capacity and their personal aspirations, expectations, and social roles.

Cognitive Appraisal and Coping Foundations

Underpinning the emotional and social dimensions is the Transactional Model of Stress and Coping developed by Richard Lazarus and Susan Folkman (1984). According to this theory, chronic physical symptoms operate as ongoing stressors. An individual’s psychological well-being is dictated by cognitive appraisals—primary appraisal (assessing the severity of symptom threats) and secondary appraisal (evaluating personal resources and coping options). The PDQL captures the downstream emotional consequences of these appraisals, reflecting whether patients experience demoralization or maintain psychological equilibrium despite escalating neurodegenerative impairments.

7. Validity

Validation of the PDQL has been documented across clinical neurology, psychometric development literature, and comparative cross-instrument evaluations. The instrument exhibits robust construct, convergent, discriminant, and criterion-related validity.

Construct and Convergent Validity

During its initial validation by de Boer et al. (1996), construct validity was established by comparing the PDQL against validated disease-severity indices and generic health status measures. Convergent validity was evidenced by moderate-to-strong correlations between the PDQL subscales and corresponding sections of the UPDRS:

• The Parkinson Symptoms subscale demonstrated substantial negative correlations with the UPDRS Part II (Activities of Daily Living; r = -0.65 to -0.73) and UPDRS Part III (Motor Examination; r = -0.52 to -0.61), indicating that greater functional motor impairment corresponds to lower quality of life.
• The Emotional Functioning subscale demonstrated high convergent validity with established psychiatric measures, correlating strongly with the Montgomery-Åsberg Depression Rating Scale (MADRS; r = -0.68) and the Hospital Anxiety and Depression Scale (HADS; r = -0.64 to -0.71).
• Comparisons with the SF-36 generic health survey confirmed convergent patterns: the PDQL Parkinson Symptoms dimension correlated strongly with SF-36 Physical Functioning (r = 0.70), whereas the Emotional Functioning dimension correlated robustly with SF-36 Mental Health (r = 0.74).

Discriminant Validity

Discriminant validity was established through known-groups comparisons. The PDQL differentiates between patients grouped by Hoehn and Yahr clinical staging (Stages I through V). One-way analyses of variance (ANOVA) revealed significant reductions in PDQL total and subscale scores across ascending disease stages (F > 18.4, p < 0.001). Furthermore, the scale distinguishes between patients experiencing motor fluctuations (such as wearing-off phenomena and dyskinesias) and those with stable symptom control, demonstrating sensitivity to clinical distinctions that generic instruments frequently fail to register.

Criterion and Longitudinal Responsiveness

The PDQL exhibits sensitivity to therapeutic change. Longitudinal clinical investigations tracking patients undergoing bilateral subthalamic nucleus deep brain stimulation (STN-DBS) or intestinal levodopa/carbidopa gel infusion have shown marked increases in PDQL total scores post-intervention (effect sizes ranging from Cohen’s d = 0.55 to 0.82), demonstrating responsiveness to surgical and advanced pharmacological interventions.

8. Reliability

The reliability of the PDQL has been demonstrated across developmental and subsequent cross-cultural validation studies, confirming both internal consistency and temporal stability.

Internal Consistency Reliability

In the seminal validation study by de Boer et al. (1996) involving 120 patients with Parkinson’s disease, internal consistency was evaluated using Cronbach’s alpha coefficients across all four subscales and the total score. The values met or exceeded standard thresholds for group- and individual-level psychometric assessment (Nunnally & Bernstein, 1994):

• Total PDQL Scale: α = 0.93 to 0.95
• Parkinson Symptoms Subscale: α = 0.84 to 0.88
• Systemic Symptoms Subscale: α = 0.73 to 0.79
• Emotional Functioning Subscale: α = 0.85 to 0.89
• Social Functioning Subscale: α = 0.76 to 0.82

Corrected item-total correlations across the subscales generally exceeded 0.40, indicating that individual items contribute coherently to their respective domains without redundant overlap.

Test-Retest Reliability

Temporal stability was evaluated across stable patient subsets assessed at a two-to-four-week retest interval. In patients reporting no clinical transition on global rating scales, the Intraclass Correlation Coefficients (ICC) and Pearson product-moment correlations were:

• Total Score ICC: 0.89 (95% CI: 0.83–0.93)
• Parkinson Symptoms ICC: 0.86
• Systemic Symptoms ICC: 0.78
• Emotional Functioning ICC: 0.85
• Social Functioning ICC: 0.81

The standard error of measurement (SEM) and smallest detectable change (SDC) statistics confirm that the PDQL possesses acceptable measurement precision for monitoring clinical courses over time.

9. Factor Analysis

The internal structural integrity of the PDQL was developed and verified using exploratory factor analysis (EFA) and subsequent confirmatory factor analysis (CFA) across diverse international adaptations.

Exploratory Factor Analysis (EFA)

During initial scale development, the exploratory item pool was subjected to principal component analysis (PCA) followed by orthogonal (Varimax) and oblique (Promax) rotations to account for theoretical correlations among quality-of-life facets. Initial eigenvalues and scree plot examination identified four prominent factors with eigenvalues strictly greater than 1.0 (Kaiser-Guttman criterion), explaining over 52% of the total cumulative variance in the item set:

• Factor 1 (Parkinson Symptoms): Accounted for approximately 28.4% of the initial variance, characterized by primary loadings from items detailing gait freeze, postural instability, tremor, and motor activities. Salient item loadings ranged from 0.52 to 0.81.
• Factor 2 (Emotional Functioning): Accounted for approximately 11.2% of the variance, with loadings ranging from 0.48 to 0.78 on items tapping nervousness, depressive thoughts, frustration, and disease-related existential angst.
• Factor 3 (Social Functioning): Explained 7.1% of the variance, capturing items related to public participation, communication difficulties, leisure activities, and interpersonal relationships, with loadings from 0.46 to 0.75.
• Factor 4 (Systemic Symptoms): Accounted for 5.8% of the variance, loaded primarily by items addressing fatigue, sleep quality, pain, and gastrointestinal issues, with factor loadings between 0.41 and 0.72.

Confirmatory Factor Analysis (CFA) and Goodness-of-Fit

Subsequent validation studies applying confirmatory factor analysis have evaluated the four-factor oblique model against alternative unidimensional and hierarchical second-order models. Structural equation modeling metrics have consistently substantiated the four-factor architecture:

• Comparative Fit Index (CFI): Values typically range between 0.91 and 0.94, confirming an acceptable-to-good fit relative to the null baseline model.
• Tucker-Lewis Index (TLI): Estimates fall between 0.90 and 0.93.
• Root Mean Square Error of Approximation (RMSEA): Estimates range from 0.051 to 0.064 (with 90% confidence intervals bounded below 0.075), indicating low residual error.
• Standardized Root Mean Square Residual (SRMR): Values consistently settle below the conventional 0.08 benchmark (averaging 0.062).

Inter-factor correlations within the CFA model range from 0.42 to 0.68, demonstrating that while the four subscales are conceptually unified under the global umbrella of Parkinson’s disease-related quality of life, they maintain sufficient empirical distinctiveness to preclude multidimensional redundancy.

10. Instrument / Measurement Tool

The Parkinson’s Disease Quality of Life questionnaire is structured as follows:

• Measurement Format: Standardized self-administered questionnaire or interviewer-assisted survey.
• Total Number of Items: 37 items.
• Recall Timeframe: The preceding three months (“During the past three months…”).
• Subscale Architecture (4 Dimensions):
  • Parkinson Symptoms: 8 items
  • Systemic Symptoms: 7 items
  • Emotional Functioning: 9 items
  • Social Functioning: 13 items (in the extended 37-item operationalization, distributed across interpersonal leisure, communication, and social contact)
• Response Scale: 5-point Likert scale formatted with frequency- or severity-based anchors:
  • 1 = All the time / Permanently / Extremely
  • 2 = Often / Frequently / Much
  • 3 = Sometimes / Moderately
  • 4 = Rarely / Seldom / A little
  • 5 = Never / Not at all
• Scoring Algorithm:
  • Subscale Scores: Calculated by summing the raw item scores corresponding to each subscale. Alternatively, raw totals can be converted into a standardized score ranging from 0 to 100 via linear transformation: Transformed Score = [(Raw Score − Minimum Possible Score) / (Maximum Possible Score − Minimum Possible Score)] × 100.
  • Total Score: The summary score ranges from 37 (poorest possible HRQoL, maximum symptom interference) to 185 (optimal HRQoL, zero symptom interference).
  • Directionality: Higher scores consistently represent superior health-related quality of life and lower subjective symptom interference.
• Administration Time: Approximately 10 to 15 minutes for independent self-completion; 15 to 20 minutes when administered by an interviewer.

11. Permissions & Fee and Test Year

The Parkinson’s Disease Quality of Life questionnaire was formally published in 1996 by Angela G. E. M. de Boer and colleagues in the Journal of Neurology, Neurosurgery, and Psychiatry. The copyright for the original publication is held by the authors and the BMJ Publishing Group.

For academic research, non-commercial clinical investigations, and routine hospital practice, the PDQL is generally available without licensing fees upon proper attribution and reference to the original 1996 publication. However, commercial entities, industry-sponsored clinical trials, pharmaceutical studies, and electronic health record (EHR) software vendors must obtain formal permission or licensing agreements. Researchers seeking official authorized translations, manual guidelines, or digital reproduction permissions should contact the corresponding author, the Department of Medical Psychology at the Academic Medical Center (now Amsterdam University Medical Centers), or the publisher via the Copyright Clearance Center.

12. References

• de Boer, A. G. E. M., Wijker, W., Speelman, J. D., & de Haes, J. C. J. M. (1996). Quality of life in patients with Parkinson’s disease: Development of a questionnaire. Journal of Neurology, Neurosurgery, and Psychiatry, 61(1), 70–74. https://doi.org/10.1136/jnnp.61.1.70
• Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 196(4286), 129–136. https://doi.org/10.1126/science.847460
• Hobson, P., Holden, A., & Meara, J. (1999). Measuring the impact of Parkinson’s disease with the Parkinson’s Disease Quality of Life questionnaire. Age and Ageing, 28(4), 341–346. https://doi.org/10.1093/ageing/28.4.341
• Lazarus, R. S., & Folkman, S. (1984). Stress, Appraisal, and Coping. Springer Publishing Company.
• Martinez-Martin, P. (1998). An introduction to the concept of “quality of life” in Parkinson’s disease. Journal of Neurology, 245(Suppl 1), S2–S6. https://doi.org/10.1007/pl00007733
• Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric Theory (3rd ed.). McGraw-Hill.
• Peto, V., Jenkinson, C., Fitzpatrick, R., & Greenhall, R. (1995). The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease (the PDQ-39). Quality of Life Research, 4(3), 241–248. https://doi.org/10.1007/BF02260863
• Verbrugge, L. M., & Jette, A. M. (1994). The disablement process. Social Science & Medicine, 38(1), 1–14. https://doi.org/10.1016/0277-9536(94)90294-1
• Ware, J. E., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30(6), 473–483. https://doi.org/10.1097/00005650-199206000-00002

13. Items of the Scale